BZYR - BURZYNSKI RESEARCH INSTITUTE INC
0.0203
-0.002 -11.823%
Share volume: 8,218
Last Updated: 03-27-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.05%
PREVIOUS CLOSE
CHG
CHG%
$0.02
0.00
-0.11%
View ratios
| Fiscal Date | 05-31-2025 | 08-31-2025 | 11-30-2025 | |
|---|---|---|---|---|
| Fiscal Quarter | Q1 2025 | Q2 2026 | Q3 2026 | |
| Report Date | 07-15-2025 | 10-14-2025 | 01-13-2026 | |
| Cash flow financing | 49.117 K | 0.000 | 824.340 K | |
| Other financing cash flows | 49.117 K | 0.000 | 824.340 K | |
| Cash flow | -26.000 | 0.000 | 0.000 | |
| Net income | -331.451 K | -333.867 K | -328.862 K | |
| Depreciation | 0.000 | 0.000 | 0.000 | |
| Changes in inventories | 0.000 | 0.000 | 0.000 | |
| Changes in receivables | 0.000 | 0.000 | 0.000 | |
| Investing Cashflow | 0.000 | 0.000 | 0.000 | |
| Net Borrowings | 0.000 | 0.000 | 0.000 | |
| Investing Activity Other | 0.000 | 0.000 | 0.000 | |
| Dividends Paid | 0.000 | 0.000 | 0.000 | |
| Exchange Rate Effect | 0.000 | 0.000 | 0.000 | |
| Capital Expenditures | 0.000 | 0.000 | 0.000 | |
| Cash Change | -26.000 | 0.000 | 1.234 K |